Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorRenJi Hospital
About this trial
To explore the safety and efficacy of Albumin-Bound Paclitaxel/Platinum based concurrent chemoradiotherapy Followed by PD-1 inhibitor (Sintilimab) in locally advanced cervical cancer
Eligibility criteria
Qualifiers
Age between 18 and 75;
Untreated patients with pathologically proven locally advanced cervical cancer;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
Life expectancy > 6 months
Disqualifiers
Recurrent or distant metastatic disease;
Prior malignancies (other than curable non-melanoma skin cancer) within 5 years;
Active autoimmune diseases requiring systemic treatment or other diseases requiring long-term use of substantial amount of hormones or other immunosuppressants;
Patients who need to receive systemic corticosteroids (dose equivalent to or higher than prednisone 10mg qd) or other immunosuppressants within 14 days before enrollment or during the study;
Trial design
Treatments tested in this trial
- Albumin-Bound Paclitaxel, cisplatin, Sintilimab
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov